aTyr Pharma (ATYR) vs TScan Therapeutics (TCRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
aTyr Pharma (ATYR) has outperformed TScan Therapeutics (TCRX) over the past year, losing 74.2% versus a loss of 89.0%. Over five years, TCRX leads with a -96.5% price change compared with -97.2% for ATYR. aTyr Pharma is the larger company by market cap ($24.1 million vs $16.1 million), about 1.5 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ATYR | TCRX |
|---|---|---|
| Share price | $0.2462 | $0.238 |
| Market cap | $24.15M | $16.13M |
| 1-day change | -3.56% | +4.29% |
| YTD return | -68.56% | -76.20% |
| 1-year return | -74.17% | -89.03% |
| 5-year return | -97.17% | -96.47% |
| EPS (TTM) | $-0.59 | $-0.92 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.11 | $2.57 |
| 52-week low | $0.246 | $0.224 |
| Distance from 52-week high | -77.82% | -90.74% |
| Analyst consensus | buy | hold |
| Avg. price target upside | +1061.66% | +320.17% |
| Average volume | 3.27M | 784.00K |
| Shares outstanding | 98.09M | 63.50M |
| Employees | 58 | 138 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ATYR has outperformed TCRX by 14.9 percentage points over the past year.
About aTyr Pharma
ATYR stock →aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinical trial to treat Sarcoidosis and systemic sclerosis- interstitial lung disease (ILDs); and treatment of other ILDs, such as chronic hypersensitivity pneumonitis (CHP) and connective tissue disease related ILD.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 58 employees
About TScan Therapeutics
TCRX stock →TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 138 employees
ATYR vs TCRX FAQ
Which is bigger, aTyr Pharma or TScan Therapeutics?
aTyr Pharma (ATYR) is larger, with a market capitalization of $24.15M compared with $16.13M for TScan Therapeutics (TCRX).
Which stock has performed better over the past year, ATYR or TCRX?
ATYR returned -74.17% over the past 12 months, compared with -89.03% for TCRX (price return, excluding dividends). Past performance does not predict future results.
Are aTyr Pharma and TScan Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.